Portugal Spain France Iceland UK Ireland Belgium Netherlands Germany Denmark Norway Finland Sweden Switzerland Italy Austria Czech Republik Slovakia Croatia Poland Hungary Romania Greece Lithuania Latvia Estonia Belarus Ukraina Serbia & Montenegro Bulgaria Moldavia Macedonia Albania
Biotechnology and Pharma Switzerland
Biotechnology and Pharma Germany
Biotechnology and Pharma Sweden
Biotechnology and Pharma   UK
Biotechnology and Pharma  Ireland
Biotechnology and Pharma  France
Biotechnology and Pharma Italy
Biotechnology and Pharma Netherlands
Biotechnology and Pharma Belgium
Biotechnology and Pharma Norway
Biotechnology and Pharma Denmark
Biotechnology and Pharma  Austria
Biotechnology and Pharma  Greece
Biotechnology and Pharma Finland
Biotechnology and Pharma Spain
Biotechnology and Pharma Hungary
Biotechnology and Pharma Russia
Biotechnology and Pharma Czech Republic
Biotechnology and Pharma Estonia
Biotechnology and Pharma Poland
Biotechnology and Pharma Portugal
Biotechnology and Pharma  Slovakia
Biotechnology and Pharma Lithuania
Biotechnology and Pharma  Iceland
Biotechnology and Pharma Slovenia
Biotechnology and Pharma Bulgaria
Biotechnology and Pharma Romania
Biotechnologyand Pharma Macedonia
Biotechnology and Pharma Albania
Biotechnology and Pharma Luxembourg
Biotechnology and Pharma Serbia
Biotechnology and Pharma Cyprus
Biotechnology and Pharma Malta
Biotechnology and Pharma Belarus
Biotechnology and Pharma Croatia
Biotechnology and Pharma Ukraina
Biotechnology and Pharma Turkey

 
 

New compound offers attractive therapeutic candidate for autoimmune inflammatory diseases
 

A new way to increase the numbers of mobilized stem cells
 

New Microneedle Applicator Device
 

Novel compound offers new treatment approach for ovarian cancer
 

A diagnostic marker for early cancer detection
 
  Sulidin® nimesulide LPS Non-Steroidal Topical Anti-inflammatory gel for the local treatment of painful inflammatory conditions
 

 
08.07.2008 MediGene puts clinical phase I study with RhuDex® on hold
 
08.07.2008 SomnoMed appoint Intus Healthcare as its UK distribution partner
 
07.07.2008 Early findings show promise as AS1411 AML study proceeds to higher-dose stage
 
07.07.2008 Tripep submits new application for phase II study of ChronSeal®
 
07.07.2008 Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
 
01.07.2008 Oxford Biomedica Response to Bavarian Nordic’s US Litigation
 
01.07.2008 Oxford Biomedica Announces update on board changes
 
30.06.2008 Headline results of Flurizan® in clinical phase III trial
 
30.06.2008 Ground breaking results for Tripep in the ongoing clinical trial of ChronVac-C® for the treatment of chronic hepatitis C
 
27.06.2008 AFINION HbA1c patent granted in USA
 
26.06.2008 Study Adds to Body of Evidence on KRAS Mutational Status As a Predictive Biomarker of Vectibix Response